Neumedicines Inc.

📍 Pasadena, United States🗓 Founded 2003👥 11 employees💰 Last funded Jan 2015
Biotechnology🌐 neumedicines.com
Website LinkedIn
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Neumedicines Inc.?
Neumedicines Inc. has 1 investors on record on gritt.io.
When did Neumedicines Inc. last raise funding?
The most recent investment in Neumedicines Inc. recorded on gritt.io was in January 2015.
When was Neumedicines Inc. founded?
Neumedicines Inc. was founded in 2003.
What industry is Neumedicines Inc. in?
Neumedicines Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Neumedicines Inc. based?
Neumedicines Inc. is headquartered in Pasadena, United States.